BACKGROUND: The role of radiotherapy and chemotherapy in the treatment of low-grade gliomas (LGG) is controversial regarding their effect on survival and the development of neurotoxicity. The few published studies examining adverse treatment effects on cognition revealed conflicting results. OBJECTIVE: To assess cognitive functioning in LGG patients who received conformal radiation therapy (RT), chemotherapy, or no treatment. DESIGN: 40 LGG patients participated in the study; 16 patients had RT +/- chemotherapy, and 24 patients had no treatment. All patients underwent a neuropsychological evaluation. APOE genotype was obtained in 36 patients who were classified in two groups based on the presence or absence of at least one apolipoprotein E small je, Ukrainian-4 (APOE small je, Ukrainian-4) allele. RESULTS: Treated LGG patients had lower scores than untreated patients on several cognitive domains; patients who completed treatment at intervals greater than 3 years and had long disease duration had significantly lower scores on the Non-Verbal Memory domain. Antiepileptic polytherapy, treatment history, and disease duration jointly contributed to low Psychomotor domain scores. 62% of treated patients showed white matter confluence on MRI, whereas only 9% of the untreated patients had such changes. Preliminary comparisons between APOE small je, Ukrainian-4 carriers (n = 9) and non-carriers (n = 27) on cognitive domain scores revealed no statistically significant differences, but APOE small je, Ukrainian-4 carriers had lower mean scores on the Verbal Memory domain than did non-small je, Ukrainian-4 carriers. CONCLUSIONS: RT +/- chemotherapy, disease duration, and antiepileptic treatment contributed to mild cognitive difficulties in LGG patients.
BACKGROUND: The role of radiotherapy and chemotherapy in the treatment of low-grade gliomas (LGG) is controversial regarding their effect on survival and the development of neurotoxicity. The few published studies examining adverse treatment effects on cognition revealed conflicting results. OBJECTIVE: To assess cognitive functioning in LGG patients who received conformal radiation therapy (RT), chemotherapy, or no treatment. DESIGN: 40 LGG patients participated in the study; 16 patients had RT +/- chemotherapy, and 24 patients had no treatment. All patients underwent a neuropsychological evaluation. APOE genotype was obtained in 36 patients who were classified in two groups based on the presence or absence of at least one apolipoprotein E small je, Ukrainian-4 (APOE small je, Ukrainian-4) allele. RESULTS: Treated LGG patients had lower scores than untreated patients on several cognitive domains; patients who completed treatment at intervals greater than 3 years and had long disease duration had significantly lower scores on the Non-Verbal Memory domain. Antiepileptic polytherapy, treatment history, and disease duration jointly contributed to low Psychomotor domain scores. 62% of treated patients showed white matter confluence on MRI, whereas only 9% of the untreated patients had such changes. Preliminary comparisons between APOE small je, Ukrainian-4 carriers (n = 9) and non-carriers (n = 27) on cognitive domain scores revealed no statistically significant differences, but APOE small je, Ukrainian-4 carriers had lower mean scores on the Verbal Memory domain than did non-small je, Ukrainian-4 carriers. CONCLUSIONS: RT +/- chemotherapy, disease duration, and antiepileptic treatment contributed to mild cognitive difficulties in LGG patients.
Authors: B E Tardiff; M F Newman; A M Saunders; W J Strittmatter; J A Blumenthal; W D White; N D Croughwell; R D Davis; A D Roses; J G Reves Journal: Ann Thorac Surg Date: 1997-09 Impact factor: 4.330
Authors: M J Taphoorn; A K Schiphorst; F J Snoek; J Lindeboom; J G Wolbers; A B Karim; P C Huijgens; J J Heimans Journal: Ann Neurol Date: 1994-07 Impact factor: 10.422
Authors: Anders M Fjell; Kristine B Walhovd; Ivar Reinvang; Arvid Lundervold; Anders M Dale; Brian T Quinn; Nikos Makris; Bruce Fischl Journal: J Int Neuropsychol Soc Date: 2005-01 Impact factor: 2.892
Authors: Tim A Ahles; Andrew J Saykin; Walter W Noll; Charlotte T Furstenberg; Stephen Guerin; Bernard Cole; Leila A Mott Journal: Psychooncology Date: 2003-09 Impact factor: 3.894
Authors: Florien W Boele; Maaike Zant; Emma C E Heine; Neil K Aaronson; Martin J B Taphoorn; Jaap C Reijneveld; Tjeerd J Postma; Jan J Heimans; Martin Klein Journal: Neurooncol Pract Date: 2014-05-06
Authors: Rohit R Das; Elinor Artsy; Shelley Hurwitz; Patrick Y Wen; Peter Black; Alexandra Golby; Barbara Dworetzky; Jong Woo Lee Journal: J Neurooncol Date: 2012-01-03 Impact factor: 4.130
Authors: Denise D Correa; Weiji Shi; Howard T Thaler; Angeles M Cheung; Lisa M DeAngelis; Lauren E Abrey Journal: J Neurooncol Date: 2007-10-10 Impact factor: 4.130
Authors: Kristin M Rankin; Garth H Rauscher; Bridget McCarthy; Serap Erdal; Pat Lada; Dora Il'yasova; Faith Davis Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-10 Impact factor: 4.254